Treatment of Pouchitis with Dehydroepiandrosterone (DHEA) - A Case Report

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 11, 2003, Pages 1087-1090

  Klebl, Frank H ^a,c   Bregenzer, N ^a   Rogler, G ^a   Straub, R H ^a   Scholmerich J ^a   Andus, T ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Klinikum Stuttgart Krankenhaus Bad Cannstatt   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Dehydroepiandrosterone; Pouchitis; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOPERAMIDE; MESALAZINE; METRONIDAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRASTERONE;

ABDOMINAL PAIN; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE REPORT; ENDOSCOPY; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; ILEITIS; PILOT STUDY; POSTOPERATIVE COMPLICATION; PROCTOCOLECTOMY; ULCERATIVE COLITIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; COLITIS, ULCERATIVE; DEHYDROEPIANDROSTERONE; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; POUCHITIS; TIME FACTORS;

EID: 0345415016     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-44306     Document Type: Article

References (18)

1. Gionchetti P, Amadini C, Rizzello F et al. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther 2002; 16: 13-19 (Suppl 4)
2. Straub RH, Vogl D, Gross V et al. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol 1998; 93: 2197-2202
3. Straub RH, Lehle K, Herfarth H et al. Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor. Eur J Endocrinol 2002; 146: 365-374
4. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32 833-32 841
5. Cheng GF, Tseng J. Regulation of murine interleukin-10 production by dehydroepiandrosterone. J Interferon Cytokine Res 2000; 20: 471-478
6. Andus T, Klebl F, Rogler G et al. Patients with refractory Crohn's disease and ulcerative colitis respond to dehydroepiandrosterone in a pilot study. Aliment Pharmacol Ther 2003; 17: 409-414
7. Meagher AP, Farouk R, Dozois RR et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: Complications and long-term outcome in 1310 patients. Br J Surg 1998; 85: 800-803
8. Sandborn WJ, McLeod R, Jewell DP. Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm Bowel Dis 1999; 5: 33-39
9. Shen B, Achkar JP, Lashner BA et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-305
10. Mimura T, Rizzello F, Helwig U et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002; 16: 909-917
11. Sambuelli A, Boerr L, Negreira S et al. Budesonide enema in pouchitis-a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002; 16: 27-34
12. Miglioli M, Barbara L, Di Febo G et al. Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis. N Engl J Med 1989; 320: 257
13. Kuzela L, Kascak M, Vavrecka A. Induction and maintenance of remission with non-pathogenic Escherichia coli in patients with pouchitis. Am J Gastroenterol 2001; 96: 3218-3219
14. Chang DM, Lan JL, Lin HY et al. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 2924-2927
15. Petri MA, Lahita RG, van Vollenhoven RF et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomised, placebo-controlled trial. Arthritis Rheum 2002; 46: 1820-1829
16. Allolio B, Arlt W. DHEA treatment: myth or reality? Trends Endocrinol Metab 2002; 13: 288-294
17. Dyner TS, Lang W, Geaga J et al. An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. J Acquir Immune Defic Syndr 1993; 6: 459-465
18. Kroboth PD, Salek FS, Pittenger AL et al. DHEA and DHEA-S. a review. J Clin Pharmacol 1999; 39: 327-348